Physician profile
Jay Shah
NPI 1285166264
$6,070.61
in general payments reported to CMS, 2019-2025
27 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $107 · 2021: $270 · 2022: $1,093 · 2023: $738 · 2024: $2,719 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,858 · Honoraria: $900 · Travel and Lodging: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,857.75 |
| Honoraria | $900.00 |
| Travel and Lodging | $843.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,740.15 | 2022-2025 | Impella |
| Abbott Laboratories | $1,727.50 | 2023-2025 | Optis, Perclose Prostyle, Aveir |
| Shockwave Medical, INC | $445.76 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $381.57 | 2021-2023 | Euphora |
| Astrazeneca Pharmaceuticals Lp | $220.13 | 2021-2022 | |
| Teleflex LLC | $219.45 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.46 | 2020-2022 | |
| Boston Scientific Corporation | $140.10 | 2021-2024 | Eluvia |
| Impulse Dynamics (USA) INC. | $128.05 | 2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $115.81 | 2022 | |
| Angiodynamics, INC. | $102.33 | 2023 | Alphavac |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $90.36 | 2022-2023 | Lifevest |
| Esperion Therapeutics, INC. | $85.48 | 2020 | |
| Kestra Medical Technology Services, INC. | $80.38 | 2025 | Assure Wcd |
| Pfizer INC. | $71.84 | 2022-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $63.92 | 2025 | Repatha |
| Chiesi USA, INC. | $56.51 | 2025 | Kengreal |
| Cordis US Corp. | $36.60 | 2023-2025 | Mynxgrip |
| Janssen Pharmaceuticals, INC | $35.47 | 2024 | Xarelto |
| Philips North America LLC | $32.93 | 2024-2025 | (5044) Mcot, Mcot |
| Merck Sharp & Dohme LLC | $32.54 | 2022-2025 | Keytruda Qlex, Keytruda |
| Novartis Pharmaceuticals Corporation | $29.89 | 2023 | |
| Medline Industries Lp | $19.45 | 2022 | |
| Getinge USA Sales, LLC | $18.35 | 2022 | |
| La Jolla Pharmaceutical Company | $17.38 | 2025 | Giapreza |
| Terumo Medical Corporation | $16.60 | 2023 | Glidesheath Slender |
| Janssen Biotech, INC. | $15.60 | 2024 | Stelara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.